Many law firms have litigators.  Many law firms have patent lawyers.  Axinn offers patent litigators with national reputations as trial lawyers and deep training and experience as patent counselors.  The firm has an extensive record of successfully litigating high-stakes patent cases and trying them to verdict.  Axinn also offers extensive experience and understanding of PTO practice and procedure, and serves as counsel in numerous contested proceedings.

Representative litigation experience includes:

• Trial for Johnson & Johnson in case involving medical devices
• Trial for Actavis in pharmaceutical case involving billions of dollars in potential damages
• Multiple trials and appeals in pharmaceutical cases
• Litigation in many cases involving tools and hardware

• Litigation for Unilever in case involving non-butter spreads
• Trial for 3M in case involving filtration devices
• Litigation for FILA in cases involving sneakers and articulated-toe footwear
• Litigation for URL Mutual of preliminary injunction hearing and Federal Circuit appeal
• Litigation for New York Community Bank in case involving business methods patents
• Litigation for R.R. Donnelley in cases involving gift and phone card technologies
• Litigation in many cases involving tools and hardware

Representative industry experience includes:

• Biotech.  Axinn’s team is led by lawyers and professionals with advanced degrees and industry experience in areas such as organic chemistry, microbiology and immunology.  Axinn provides counseling, regulatory and litigation services in the areas of biologics, diagnostics and human tissues, including technologies and therapies targeted to cancer, autoimmune disease and reconstructive surgery.
• Chemicals.  Many Axinn attorneys are chemists and chemical engineers.  They practice in areas such as coating compositions, cosmetics, topical compositions, specialty chemicals, polymers, process engineering, surfactants and water treatment chemicals.
• Mechanical.  Axinn attorneys have extensive experience in numerous industries and hold specialized degrees in fields such aeronautical engineering, civil engineering, computer science and mechanical engineering.  Axinn has served clients in a variety of industries, including aerospace, apparel, athletic gear, automotive, consumer products, hand and power tools, manufacturing and industrial processes.
• Medical Devices.  Using the experience of its mechanical, electrical and life-sciences trained attorneys, the firm helps its clients across a broad range of different technologies, including spinal implants, stents, catheters, blood pressure sensors, contrast agents and wound dressings.
• Pharmaceuticals.  Axinn offers the leading pharmaceutical practice in the country.  It also combines its deep substantive and litigation experience with its FDA, antitrust, and commercial litigation practice areas to offer clients a unique end-to-end solution. 
• Technology.  Axinn offers the experience and skills necessary to assist clients in the information age, including software development, systems consulting and electrical engineering. The firm has represented companies in industries such as electronic equipment, semiconductors, software and e-commerce.  The firm also has extensive experience representing insurance, financial services and other companies in connection with business methods patents, and has a particular interest in defending clients in actions brought by non-practicing entities.

Axinn partners with its clients to provide day-to-day intellectual property advice, to formulate strategic plans and to execute those strategies, including in the courtroom.  Axinn attorneys also perform IP due diligence, audits and analyses, provide counseling services for all major corporate transactions and draft license agreements and other contracts.

News

• Axinn Ranks Among Nation’s Top Firms in 2023 ANDA Intelligence Report
• Axinn Shortlisted for Three 2023 LMG Life Sciences Americas Awards
• Axinn and IP Partners Ranked by IAM Patent 1000: The World’s Leading Patent Professionals
• Managing IP STARS Selected Axinn IP Partner Jeannine Yoo Sano as a 2023 Patent Star in CA
• Axinn Scores Multiple IPR Victories on Behalf of Applied Materials
• Axinn Partners Named Life Sciences Stars by LMG Life Sciences
• Litigator of the Week Honors for Patent Trial Success
• Axinn Achieves Trial Success for Norwich Pharmaceuticals as it Seeks to Market a Generic of Xifaxan®
• Axinn and IP Partners Ranked by IAM Patent 1000: The World’s Leading Patent Professionals
• Managing IP STARS Selected Axinn IP Partner Jeannine Yoo Sano as a 2022 Patent Star in CA and Recommended Axinn in CT for IP
• Axinn and IP Partners Ranked by IAM Patent 1000: The World’s Leading Patent Professionals
• Axinn and IP Partners Ranked by IAM Patent 1000: The World’s Leading Patent Professionals
• Axinn Named a "Legal Lion" for Federal Circuit Patent Win
• Axinn Recognized in Eight Categories of "Best Law Firms" Report
• Seven Axinn Partners Named to the 2018 List of Best Lawyers in America
• Who's Who Legal Recognizes Seven Axinn Attorneys
• Axinn Obtains Denial of a TRO Motion for Client Zydus
• Axinn Earns Six Tier 1 Categories in "Best Law Firms"
• Federal Circuit Rules for Axinn Client in Tamiflu Patent Appeal
• View More ›

Articles & Newsletters

• 3 Areas Look Ripe for New SEP Licensing, Litigation
• Axinn IP Update: Federal Circuit Applies Lead Compound Analysis and Confirms Obviousness of Deuterated Derivatives of Ruxolitinib
• How to Avoid the Section 101 Pitfall in Blockchain Patenting
• Axinn IP Update: Federal Circuit Clarifies Permissible Scope of Petitioner Reply
• Axinn IP Update: District of Delaware Magistrate Judge Recommends Dismissal of Claims of Induced Infringement in Skinny Label Case
• 'Intended Purpose' of a Flower: Gauging Patent Invalidity Based on the Public Use of Plants and Genetic Information
• Supreme Court Confirms Full Scope Enablement Standard in Amgen v. Sanofi
• Effects of GSK v Teva Ripple after SCOTUS Denies Cert
• USPTO’s ANPRM Sets the Stage for Latest Revamp of the Discretionary Denial Process
• Axinn IP Update: The Supreme Court Hears Arguments About the Enablement Standard in Amgen v. Sanofi
• Federal Circuit Reverses Course on ‘Appropriate Deference’ in Indefiniteness Determinations
• Pharmaceutical Supply Chain – Patent Considerations
• The Uncertain Future of Patent Indefiniteness Under Federal Circuit's Deference Standard
• How Justice Barrett’s Confirmation Might Impact Patent Eligibility
• Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman
• Open Source Patent Licenses: Pitfalls and Opportunity
• Axinn Patent Attorneys Talk ACA Pushback and the BPCIA
• Attorney-Client Privilege in the United States: Recent Trends in its Application to Japanese Patent Professionals
• Insulin Under the BPCIA: Opportunities and Obstacles
• Navigating Uncertainty in Digital Health Patent Eligibility
• What ACA's Uncertain Future Means for Biologics Patents
• Quest Integrity v. Cokebusters Puts Cloud-Based Medical Diagnostic Patents at Risk of On-Sale Bar
• Method of Treatment Eligibility
• Axinn IP Update: Federal Circuit Addresses BPCIA Safe Harbor, Damages
• 3 Strategies to Manage Case Scope in ANDA Patent Litigation
• Little Impact Post-Arthrex for Biologic Patents at the PTAB
• U.S. Government Patent Enforcement: A Ripple or a Coming Tempest?
• Fed Circ. Ruling May Affect Eligibility of Life Sciences Patents
• Axinn IP Update: Section 287(c) Immunity Has Its Limits
• Curing the Drug Label as Prior Art Malady at the PTAB
• New Calif. Pay-For-Delay Law May Hurt Those It Aims to Help
• Patent Dance Developments: A Tale of 2 Antibodies
• Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, Second Edition
• View More ›